Cardiovascular and functional consquences of chronic kidney disease in older people - consquences of chronic kidney disease in older people

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-003998-27-GB

Enrollment

Unknown

Registered

2011-03-31

Start date

2007-03-15

Completion date

Unknown

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease Hypertension Falls

Interventions

Product Name: Antiadrenergic agents, peripherally acting Pharmaceutical Form: Tablet INN or Proposed INN: DOXAZOSIN CAS Number: 74191-85-8 Product Name: Low Ceiling Diuretics, Thiazides Pharmaceutica

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age > 70 Chronic kidney disease 3, 4 or hypertensive (> 130/80) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Likely to develop chronic kidney disease within one year Poor mobility precluding completion of assessment BP prior to antihypertensive withdrawl > 160/90 diabetes Severe peripheral vascular disease Heart failure (BYHA III/IV) or other cause to prevent diuretic withdrawl Atrial fibrillation (precludes PWV measurement) AMT <8 Recent acute illness (within the last 3 months) IHD requiring beta-bloackade (nitrates/nicorandil are permitted) Obstructive uropathy Malignant hypertension Involvement in another clinical trial with in 3 months Attending day hospital or attanding Falls Reduction Services Residents in nursing or residential homes Renovascular disease precluding ACEi/ARB usage Currently taking antihypertensive medication for which CTA has not been granted

Design outcomes

Primary

Measure	Time frame
Main Objective: The main objective is to try to answer the question "How does the change in baroreflex sensitivity alter in older people with chronic kidney disease with an optimal antihypertensitive strategy and over time?";Secondary Objective: To ascertain if the change in baroreflex sensitivity exhibited in older people with chronic kidney disease is different to that exhibited by older people who o not have chronic kidney disease. To identify abnormalities of cardiovascular function or functional ability that predict falls;Primary end point(s): change in baroreflex sensitivity with optimal hypertensive treatment and over time	—

Measure

Time frame

Main Objective: The main objective is to try to answer the question "How does the change in baroreflex sensitivity alter in older people with chronic kidney disease with an optimal antihypertensitive strategy and over time?";Secondary Objective: To ascertain if the change in baroreflex sensitivity exhibited in older people with chronic kidney disease is different to that exhibited by older people who o not have chronic kidney disease. To identify abnormalities of cardiovascular function or functional ability that predict falls;Primary end point(s): change in baroreflex sensitivity with optimal hypertensive treatment and over time

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026